1H-indazol-5-ylurea

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 1H-indazol-5-ylurea
• 化学式: C₈H₈N₄O
• 分子量: 176.18
• InChiKey: SRMGGABAHROYCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.8
• 氢给体数：
  3
• 氢受体数：
  2

文献信息

• Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
  申请人：——

  公开号：US20020198198A1

  公开（公告）日：2002-12-26

  The invention provides compounds which are PDE7inhibitors, having the following formula (I), (II) and (III) 1 in which X 1 , X 2 , X 3 , X 4 , X, Y, Z, A and Z 1 are as defined in the description, methods for preparing them and their use for the treatment of disorders for which therapy by a PDE7 inhibitor is relevant.

  本发明提供PDE7抑制剂化合物，具有以下公式（I），（II）和（III）：其中X1，X2，X3，X4，X，Y，Z，A和Z1如描述中所定义，制备它们的方法以及它们用于治疗需要PDE7抑制剂治疗的疾病的用途。
• [EN] NEW SPIROTRICYCLIC DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS<br/>[FR] NOUVEAUX DERIVES SPIROTRICYCLIQUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA PHOSPHODIESTERASE-7
  申请人：WARNER LAMBERT CO

  公开号：WO2002074754A1

  公开（公告）日：2002-09-26

  The invention provides compounds which are PDE7 inhibitors, having the following formula (I), (II) and (III), in which X1, X2, X3, X4, X, Y, Z, A and Z1 are as defined in the description, methods for preparing them and their use for the treatment of disorders for which therapy by a PDE7 inhibitor is relevant.

  本发明提供了以下式子(I)、(II)和(III)的化合物，它们是PDE7抑制剂，其中X1、X2、X3、X4、X、Y、Z、A和Z1如描述中所定义，以及制备它们的方法和它们在治疗需要PDE7抑制剂治疗的疾病中的用途。
• New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors
  申请人：Bernardelli Patrick

  公开号：US20070049558A1

  公开（公告）日：2007-03-01

  The invention provides compounds which are PDE7 inhibitors, having the following formula (I), (II) and (III) in which X 1 , X 2 , X 3 , X 4 , X, Y, Z, A and Z 1 are as defined in the description, methods for preparing them and their use for the treatment of disorders for which therapy by a PDE7 inhibitor is relevant.

  本发明提供了以下式子(I)、(II)和(III)的PDE7抑制剂化合物，其中X1、X2、X3、X4、X、Y、Z、A和Z1的定义如说明书中所述，以及制备它们的方法和它们用于治疗需要PDE7抑制剂治疗的疾病的用途。
• CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY
  申请人：Jadhav Ravindra Dnyandev

  公开号：US20120214854A1

  公开（公告）日：2012-08-23

  Heteroaryl compounds, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or disorders mediated by Diacylglycerol acyltransferase (DGAT) enzyme, particularly DGAT-1 is described.

  本文描述了杂环芳基化合物的制备方法、含有它们的制药组合物，以及它们在治疗由Diacylglycerol acyltransferase (DGAT)酶介导的疾病或紊乱中的应用，特别是DGAT-1。
• New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
  申请人：Warner-Lambert Company LLC

  公开号：EP1801106A2

  公开（公告）日：2007-06-27

  The invention provides compounds which are PDE7 inhibitors, having the following formula (I), (II) and (III), in which X1, X2, X3, X4, X, Y, Z, A and Z1 are as defined in the description, methods for preparing them and their use for the treatment of disorders for which therapy by a PDE7 inhibitor is relevant.

  本发明提供了具有下式(I)、(II)和(III)的PDE7抑制剂化合物，其中X1、X2、X3、X4、X、Y、Z、A和Z1如描述中所定义；本发明还提供了制备这些化合物的方法及其用于治疗与PDE7抑制剂治疗相关的疾病的用途。